COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Eng Hooi, Sena Anthony G, Prats-Uribe Albert, You Seng Chan, Ahmed Waheed-Ul-Rahman, Kostka Kristin, Reich Christian, Duvall Scott L, Lynch Kristine E, Matheny Michael E, Duarte-Salles Talita, Bertolin Sergio Fernandez, Hripcsak George, Natarajan Karthik, Falconer Thomas, Spotnitz Matthew, Ostropolets Anna, Blacketer Clair, Alshammari Thamir M, Alghoul Heba, Alser Osaid, Lane Jennifer C E, Dawoud Dalia M, Shah Karishma, Yang Yue, Zhang Lin, Areia Carlos, Golozar Asieh, Recalde Martina, Casajust Paula, Jonnagaddala Jitendra, Subbian Vignesh, Vizcaya David, Lai Lana Y H, Nyberg Fredrik, Morales Daniel R, Posada Jose D, Shah Nigam H, Gong Mengchun, Vivekanantham Arani, Abend Aaron, Minty Evan P, Suchard Marc, Rijnbeek Peter, Ryan Patrick B, Prieto-Alhambra Daniel
Аннотация
METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization.
RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%).
CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.